The disclosure provides multimeric proteins comprising three, four, or more monomer polypeptides, each comprising a first 4-1BB-targeting moiety, an oligomerization moiety, and optionally a linker. The monomer polypeptide may further comprise one or more additional targeting moieties. The oligomerization moiety promotes the trimerization, tetramerization, or higher state of oligomerization of the monomer polypeptides. Such multimeric proteins can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators. The present disclosure also concerns methods of making the multimeric proteins described herein as well as compositions comprising such multimeric proteins. The present disclosure further relates to nucleic acid molecules encoding such multimeric proteins and methods for the generation of such multimeric proteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such multimeric proteins as well as compositions comprising one or more of such multimeric proteins.

The disclosure provides multimeric proteins comprising three, four, or more monomer polypeptides, each comprising a first 4-1BB-targeting moiety, an oligomerization moiety, and optionally a linker. The monomer polypeptide may further comprise one or more additional targeting moieties. The oligomerization moiety promotes the trimerization, tetramerization, or higher state of oligomerization of the monomer polypeptides. Such multimeric proteins can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators. The present disclosure also concerns methods of making the multimeric proteins described herein as well as compositions comprising such multimeric proteins. The present disclosure further relates to nucleic acid molecules encoding such multimeric proteins and methods for the generation of such multimeric proteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such multimeric proteins as well as compositions comprising one or more of such multimeric proteins.

The present invention relates to ophthalmic pharmaceutical compositions in the form of oil-in-water (O/W) nanoemulsions comprising a mixture of specific components with modified physicochemical properties, in combination with an oil-xantophyll mixture for protection against blue light.

The present invention relates to ophthalmic pharmaceutical compositions in the form of oil-in-water (O/W) nanoemulsions comprising a mixture of specific components with modified physicochemical properties, in combination with an oil-xantophyll mixture for protection against blue light.

A composition and method for treating Epidermolisis bullosa (EB), comprising: applying to skin or mucosal surfaces of a patient in need of treatment for EB a dressing gauze or bandage without prior cleaning of said skin or mucosal surfaces, wherein distributed on said dressing is an effective amount of a composition containing beeswax; an oleaginous base, vitamins and a pharmaceutically acceptable excipient; then removing said dressing at least twice per day without damaging the patient's skin or mucosal surfaces due to removal of the dressing.

A composition and method for treating Epidermolisis bullosa (EB), comprising: applying to skin or mucosal surfaces of a patient in need of treatment for EB a dressing gauze or bandage without prior cleaning of said skin or mucosal surfaces, wherein distributed on said dressing is an effective amount of a composition containing beeswax; an oleaginous base, vitamins and a pharmaceutically acceptable excipient; then removing said dressing at least twice per day without damaging the patient's skin or mucosal surfaces due to removal of the dressing.

Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).

Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).

The present invention relates to methods and compositions comprising viable spores of Bacillus thuringiensis (Bt) strains for controlling or reducing mite infestations, such as the control and reduction of infestations produced by Dermanyssus gallinae (poultry red mite).

The present invention relates to methods and compositions comprising viable spores of Bacillus thuringiensis (Bt) strains for controlling or reducing mite infestations, such as the control and reduction of infestations produced by Dermanyssus gallinae (poultry red mite).